On April 29 and 30, the European consortium TANGERINE, led by Dr. Víctor Moreno, held its final follow-up meeting at the Henri Mondor Hospital in Créteil, France.
This initiative, launched in 2023, brings together teams from five countries (Spain, France, Germany, Romania, and Israel) with the goal of developing an artificial intelligence tool capable of predicting the response and toxicity to immunotherapy in patients with different types of cancer.
This study was funded by the Carlos III Health Institute (ISCIII) under the "International Collaboration Projects" program, which finances actions of the Recovery and Resilience Facility (RRF), through project AC22/00021, by the Spanish Scientific Foundation, and by the European Union – NextGenerationEU.
Link to project